Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5253 - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Non-Small Cell Lung Cancer


Dimitris Mavroudis


Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268


D. Mavroudis1, C. Papadaki2, A. Monastirioti2, K. Rounis3, G. Stoupis3, D. Makrakis3, M. Markaki4, K. Kalbakis3, S. Agelaki3

Author affiliations

  • 1 Department Of Medical Oncology, University Hospital of Heraklion (PAGNI), 715 00 - Heraklion/GR
  • 2 School Of Medicine, University of Crete, 71003 - Heraklion/GR
  • 3 Department Of Medical Oncology, University Hospital of Heraklion (PAGNI), 71201 - Heraklion/GR
  • 4 Department Of Molecular Biology And Genetics, Democritus University of Thrace, 68100 - Alexandroupoli/GR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5253


Aberrant miRNA expression has been associated with DNA damage response (DDR) pathways that modulate tumor response to platinum agents. We assessed the expression of miR-21, miR-128, mir-155 and miR-181 involved in DDR pathways, in the plasma of metastatic non- small cell lung cancer (mNSCLC) patients receiving 1st-line platinum-based chemotherapy (CMT) and the levels were correlated with patients’ outcomes. We also performed bioinformatics analysis to identify putative target genes of the above miRNAs.


Plasma samples were obtained from patients (n = 128) before 1st-line CMT. miR-21, miR-128, miR-155 and miR-181 expression levels were assessed by RT-qPCR and expression was classified as high or low according to the median values. Pathway analysis was performed by Diana-Tarbase algorithm.


Mir-128 (p < 0.001), miR-155 (p < 0.001) and miR-181 (p = 0.012) were higher in mNSCLC patients compared to healthy donors. Patients with high miR-128 and miR-155 expression had shorter overall survival (OS) (p = 0.028 and p = 0.035, respectively). In multivariate analysis performance status of 2 and high miR-128 expression independently predicted for shorter OS in the whole group of patients (p = 0.003 and p = 0.026, respectively). No differences in miRNA expression were revealed among patients with adenocarcinoma (n = 79) and squamous carcinoma (SCC; n = 41). However, in the SCC subgroup, besides miR-128 and miR-155, high miR-21 and miR-181 expression were associated with shorter OS (p = 0.021, p = 0.015, p = 0.004 and p = 0.028, respectively). In multivariate analysis, miR-155 high expression independently predicted for decreased OS (p = 0.004). Integrated function and pathway analysis on miRNA predicted genes revealed that pathways related to cancer, cell cycle, apoptosis and drug resistance were significantly enriched.


Differential expression levels of DDR related miRNAs are encountered in mNSCLC patients before 1st-line platinum-based CMT and independently predict patients’ outcomes. The association of miR-155 with the prognosis of patients with SCC merits further investigation.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.